Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Monday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of OGEN opened at $0.28 on Monday. The company’s fifty day moving average price is $0.32 and its 200-day moving average price is $0.46. Oragenics has a 1-year low of $0.25 and a 1-year high of $3.43. The firm has a market capitalization of $3.42 million, a PE ratio of -0.04 and a beta of 0.38.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.